# A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

> **NCT02568306** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 93 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** NNC0165-1562
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02568306
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-05
- **Primary completion:** 2017-02-07
- **Final completion:** 2017-02-07
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568306, "A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02568306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*